Log in to your Inderes Free account to see all free content on this page.

EQL Pharma

88.6

SEK

-0.45 %

Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Market cap

2.58B SEK

Turnover

867.18K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

8.8.

2025

Interim report Q1'26

21.8.

2025

General meeting '25

5.11.

2025

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Press release5/8/2025, 6:52 AM

Carnegie Access: EQL Pharma: As expected, meets 5-year targets, but Q4 beats our expectations

Regulatory press release5/8/2025, 5:00 AM

EQL Pharma: Year-End Report April 2024 - March 2025

Press release4/23/2025, 9:03 AM

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2024/25

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release4/16/2025, 5:06 AM

Carnegie Access: EQL Pharma: On track to meet targets – Q4 preview

Press release3/24/2025, 8:54 AM

Carnegie Access: Analyspodden 325: EQL Pharma & Carnegies analytiker Arvid Necander

Press release3/11/2025, 3:14 PM

EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin)

Press release3/11/2025, 7:37 AM

Carnegie Access: EQL Pharma: Reflections from the CMD

Regulatory press release3/7/2025, 7:30 AM

EQL Pharma: New financial targets for the period 2024/25 - 2028/29

Regulatory press release2/24/2025, 8:24 AM

EQL Pharma: Nomination committee for the 2025 Annual General Meeting

Press release2/5/2025, 7:23 AM

Carnegie Access: EQL Pharma: Q3 aligned with preliminary numbers; eyes on CMD

Regulatory press release2/5/2025, 6:00 AM

EQL Pharma: Interim Report April - December 2024

Press release2/4/2025, 9:19 AM

Carnegie Access: EQL Pharma: Tough comparisons, but fuel for sustained high growth ahead

Regulatory press release1/31/2025, 11:35 AM

EQL Pharma AB completes the asset purchase of a product portfolio from Medilink A/S

Press release1/29/2025, 1:48 PM

EQL Pharma invites to Capital Markets Day, March 7, 2025

Regulatory press release1/17/2025, 2:45 PM

EQL Pharma AB successfully issues senior secured bonds

Press release1/13/2025, 10:20 AM

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2024/25

Regulatory press release1/13/2025, 7:00 AM

EQL Pharma AB (publ) contemplates to issue senior secured bonds and publishes preliminary figures as of 31 December 2024

Press release12/11/2024, 7:26 AM

Carnegie Commissioned Research: EQL Pharma: Expands portfolio with strategic asset acquisition

Regulatory press release12/10/2024, 2:08 PM

Correction: EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals

Regulatory press release12/10/2024, 1:38 PM

EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.